BCL6 and glioblastoma: Consistent with reported poor apoptosis in glioblastoma, the total number of cells with active caspase-3 was low, but reproducibly increased from control- to BCL6-siRNA treated cells, 2-fold for NZG-1003 and T98G, and 7-fold in LN18.